{"name":"Quince Therapeutics S.p.A.","slug":"quince-therapeutics-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"EryDex High dose DSP","genericName":"EryDex High dose DSP","slug":"erydex-high-dose-dsp","indication":"Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3)","status":"phase_3"},{"name":"Dex 21-P","genericName":"Dex 21-P","slug":"dex-21-p","indication":"Treatment of rheumatoid arthritis","status":"phase_2"},{"name":"EryDex Low dose DSP","genericName":"EryDex Low dose DSP","slug":"erydex-low-dose-dsp","indication":"Inflammatory and autoimmune conditions (specific indication under investigation in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"EryDex High dose DSP","genericName":"EryDex High dose DSP","slug":"erydex-high-dose-dsp","phase":"phase_3","mechanism":"EryDex High dose DSP is a dexamethasone formulation designed for enhanced delivery and bioavailability in treating inflammatory and immune-mediated conditions.","indications":["Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3)"],"catalyst":""},{"name":"Dex 21-P","genericName":"Dex 21-P","slug":"dex-21-p","phase":"phase_2","mechanism":"Dex 21-P is a glucocorticoid receptor antagonist.","indications":["Treatment of rheumatoid arthritis"],"catalyst":""},{"name":"EryDex Low dose DSP","genericName":"EryDex Low dose DSP","slug":"erydex-low-dose-dsp","phase":"phase_3","mechanism":"EryDex Low dose DSP is a dexamethasone-based formulation designed to deliver corticosteroid therapy at reduced systemic doses while maintaining local therapeutic effect.","indications":["Inflammatory and autoimmune conditions (specific indication under investigation in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPNEtVOVVEelpHTktYaW96MkNrVmVCSWpXMWFVZmRZM2Z6Sm5kODlyd0laZHBCYVN2QlExWnJ2ekxHenZ6SS03d1Y4RVl4UUJtN2Jsdk5zOTN4ZXNHdE5iQjB0YW9YMTlybmdzQUdUYUlkdEZ3SDZaN283N0dXRVY2MTBHa1pTT0VfaU5weFBXSUV3Q2RTWDhzRWdYQmc3bEU?oc=5","date":"2026-03-26","type":"pipeline","source":"Yahoo Finance","summary":"Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance","headline":"Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Are Cutting Their Estimates: Here's What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSmlRS1JITXhxQ0JRbHJndnJQei0tTkhwWG1zTWlxZXdnbEdZUnNycW9hcTVsSFliNTN6b2J3NnJ2SGZObkVtOV91NWRJTjVuV3o4NEs0c003UDlnek9hLW9rSjJIS3hqV2ktN25MY01XVUc3MWR3ZFM4WTZSclNVdmFQcFBJZjJH?oc=5","date":"2025-12-15","type":"pipeline","source":"Yahoo Finance","summary":"Time To Worry? Analysts Just Downgraded Their Newron Pharmaceuticals S.p.A. (VTX:NWRN) Outlook - Yahoo Finance","headline":"Time To Worry? Analysts Just Downgraded Their Newron Pharmaceuticals S.p.A. (VTX:NWRN) Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQOUoxQTNCQi10QmN4c0ZCVXl0NjhpMDUwZXpWZFJjdTlwR2Y4VVYxSFMzZGt5elhYUUt5eFpBLWFkRmhBZXFfSTExQkpOeXN6R0pXblE0M2x3RFVXZ20yZHBTNGxWNlpsWjc3cGZVSWI0SGFaSzc0VEpaYXg3c3g1YTltVWFkSzNzbFZTblVJbFJhNHhLYy1LUld3WGo2YnJnNnJBUUsyV0pnU1FSQWphOFcyYnRhUQ?oc=5","date":"2025-05-15","type":"trial","source":"Seeking Alpha","summary":"Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 (NASDAQ:QNCX) - Seeking Alpha","headline":"Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 (NASDAQ:QNCX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQZVVGZk1VRnM0V2tGQ1BRTDVNM3hLT1YtdnJPeTJzeVhQT3FHaVZDclVpdnltTEppYnVaRldpMldaSVZjRDB6ZVBaeHdCcUJ0UEtKRlFFUksyQ1RwTEEwQmFiTVhVdkE4anVYam9fNzQ4alpRbWxMbUlNejBJUWxqR2Q5WWVKZ2FyNFQ1enZkdzBubjltcjRzWjZlYVhVVWNsSldZSEJGVGNuQkh6ZmtqQ3pn?oc=5","date":"2024-08-19","type":"trial","source":"Seeking Alpha","summary":"Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha","headline":"Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOQjV2ZFoyd3pfanJXT0xTMlZVTmhQR2dtaUNEOGNTSjVtbkRYbi1fdUtpZHR2UENRX0J4V2NTUjZSc0hVbkI5S0xiN1o0WWt3RFI1Z2FyZmpvRHNVR21IRDBhcU04YWxUNjlGZVNVdTBrVjRZMzVwMFRobEhydzJqU3hqajlSQ0RSSHN2STBmQVlxSzdmejFkWDZmajFnZXdIVVFPZlNfRHZmcmwwa01HdzFmMy1FUQ?oc=5","date":"2023-10-23","type":"pipeline","source":"Business Wire","summary":"Quince Therapeutics Completes Acquisition of EryDel S.p.A. - Business Wire","headline":"Quince Therapeutics Completes Acquisition of EryDel S.p.A.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AJBVV95cUxOMXdyMkZTdFNxYl9GN2xJLXloSG92SmdvWUpDd3RKeTVyWjYtY0hRemJEaEVjU0NzNnpPeGh4aVNFOFV4dHk2NndmSG5WQzlvbk51SWNadXlXU3ZxandFbzJZT1BVNDctcnhxSF9nMG1wam9DYTIweTlfY1dpZlRPQkxCX2E4SXdXa0xxbTlTNFoyMzBUSmNmaWg1WllUUGtXSWtxMjV6TVdvVV9MNC0yUjl2VUZ1UEd4V0l1YlVXSE55MmtIa25wUkRvRGtVZVNXOHM4d0dYSTZ3T29lS2RHS25rVGNydXZCQ3A4Sld3MXh6UmR3eEdfMVlqNWdEbUcyRWxJa3hYNl9UdUJzQ0tpZERnajhUVEVnWXhkakNPckhFVEpsWWpXMEtqeFUtRElvS1BmcnFhMzBkMGJxUHdTQ3NwVFB1NURxbk41dExoQU5QXzZDdWdqT0VqY3o?oc=5","date":"2023-07-24","type":"regulatory","source":"Business Wire","summary":"Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity - Business Wire","headline":"Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approv","sentiment":"positive"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}